Can We Translate Precision Oncology Into Patient Trust?

The historic recalcitrance of this malignancy is largely attributed to the almost ubiquitous presence of activating mutations in the KRAS oncogene which drives aggressive biology and early metastatic dissemination throughout the body.

While traditional standards of care relying on cytotoxic chemotherapy regimens have offered only modest survival outcomes associated with significant systemic toxicity for decades, we are now welcoming the emergence of targeted therapies capable of coming to terms with the oncogenic signaling driving these tumors. Specifically, recent research has identified a precise triple node vulnerability involving the simultaneous pharmacological inhibition of KRAS, EGFR, and STAT3, which achieves durable regression of advanced and resistant pancreatic tumors in preclinical models.

The successful mapping of genetic dependencies in these tumors thus shows that established pancreatic cancer carry an intrinsic escape hatch independent of the canonical vertical MAPK axis, which requires a more comprehensive blockade. By targeting the orthogonal resistance node of STAT3 alongside primary drivers, researchers have achieved complete regression in mouse models without the emergence of resistance that typically plagues single agent therapies.

However, the translation of such sophisticated molecular milestones into clinical reality requires the integration of AI into oncology to manage the sheer volume of data from genomic sequences to medical imaging. So, physician informaticists are now primary liaising people between clinical caregivers and IT developers to ensure that these algorithmic innovations streamline workflows and do not add undue burden on healthcare providers.

These medical IT leaders also play a keyrole in mitigating biases in AI systems by establishing safeguards that prevent unequal treatment recommendations based on race or socioeconomic status. Without the deep clinical understanding that physician informaticists bring to the table, technological solutions risk being misaligned with real world clinical workflows, which may lead to suboptimal patient care or safety concerns.

In the Western Pacific region specifically, the integration of these advanced care models faces specific challenges due to the geographic dispersion of our populations and the significant wealth disparities between nations.

The region shoulders approximately 1/3 of the global cancer burden with rising incidence rates that demand a patient oriented and economically sustainable approach to the management of malignant disease.

Unfortunately, many Pacific Island Countries and Territories struggle with limited resources where fewer than 1/3 have a full time pathologist or radiologist and none have access to functioning PET scanners. This lack of resources results in patients presenting with more advanced disease and limits access to appropriate work up and treatment despite their willingness to travel great distances for care.

Moreover, the importation of clinical trials from high income countries tend to place additional burdens on local clinical staff without producing findings that are relevant to the local stakeholders or patient populations.

We learned there is a growing call for Common Sense Oncology, which advocates for a recalibration of cancer care, to focus on outcomes that matter to patients such as overall survival and quality of life. However, the cost of cancer drugs continues to pose a global problem, since although new therapies have a central position in international guidelines, they come with price tags that correlate poorly with the magnitude of clinical benefit.

For patients in the Pacific, this creates a value crisis where expensive and marginally beneficial medicines approved elsewhere may be perceived as the standard of care despite the lack of basic treatments like radiotherapy.

Beyond the economic and logistical barriers lies the influence of religion on the patient experience, which significantly impacts how Pasifika peoples engage with oncology services.

Recent qualitative studies involving Samoan and Tongan participants reveal a deep rooted belief that a cancer diagnosis inevitably leads to death. This fatalism is further exacerbated by the delivery of diagnoses in culturally insensitive ways such as over the telephone or without the presence of a support person or an interpreter to buffer the emotional impact.

The breakdown of trust between patients and healthcare providers can thus occur when patients do not feel heard or experience discrimination. In fact, Pacific peoples tend to rely on a holistic and collective approach to support where the immediate and extended family provides essential emotional, physical, and financial assistance throughout the treatment journey.

Also, it is common for patients to seek alternative therapies and traditional healing practices alongside their western medical treatment, although as we see in the medical documents we translate in languages like Chuukese, Marshallese or Palauan, fear of judgment prevents them from disclosing their secret home-made brews to their clinicians.

That is certainly because spirituality and faith has a central role as a source of strength and resilience for participants who view their church community as a provider of both spiritual prayer and practical support like meals and transport. Participants in recent studies have explicitly voiced a desire for support services driven and designed by Pacific peoples for Pacific peoples, including support groups led by those who share their language and cultural background.

We see first hand that the lack of Pacific staff within oncology services creates a representation gap where patients feel uncomfortable or shy because they do not see people who look like them or understand their cultural background.

A major stumbling block is communication, as some participants will find written information in languages like Niuean, Tokelauan or Tuvaluan very helpful, others may find it overwhelming and would prefer resources in video format. Our teams know they do enjoy videos in their own languages and we are always enthusiastic to record the audios of our own translations for them. We believe effective evidence communication must therefore involve engaging with patient groups to present new research in a balanced manner that avoids fostering false hope or promoting treatments with limited value.

By embracing collaborative efforts and expanding the roles of those who understand both the clinical and cultural terrain we can help shape a future where cancer care is responsive to the needs of all patients. As we move toward a future of precision medicine where triple node inhibitors and AI driven diagnostics become the norm, our task is to ensure the language of care translates effectively across cultural sensitivities.

The provider who understands the technicality of the cure but fails to grasp the cultural context of the patient is bound to fail and render the most advanced treatment ineffective because of the lack of trust and engagement.